Changes to the Code
H.R. 8840 · Fair Care Act of 2026 · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
2 U.S.C. § 907 The baseline
1 change the bill asks for here, 1 carried out
- Carried out:
Section 257(b)(2) of the Balanced Budget and Emergency Deficit Control Act of 1985 is amended by adding at the end the following new subparagraph:
(E) Budgetary effects of rules subject to section 922 of title 5, United States Code.— Any rules subject to the congressional approval procedure set forth in section 922 of chapter 8 of title 5, United States Code, affecting budget authority, outlays, or receipts shall be …
§ 907(b)–(c)
Start of § 907 to (b)(2)(B) unchanged ·
(C) Excise taxes dedicated to a trust fund, if expiring, are assumed to be extended at current rates.
(D) If any law expires before the budget year or any outyear, then any program with estimated current year outlays greater than $50,000,000 that operates under that law shall be assumed to continue to operate under that law as in effect immediately before its expiration.
(E) [inserted: Budgetary effects of rules subject to section 922 of title 5, United States Code.—] [inserted: Any rules subject to the congressional approval procedure set forth in section 922 of chapter 8 of title 5, United States Code, affecting budget authority, outlays, or receipts shall be assumed to be effective unless it is not approved in accordance with such section.]
(3) Hospital Insurance Trust Fund Notwithstanding any other provision of law, the receipts and disbursements of the Hospital Insurance Trust Fund shall be included in all calculations required by this Act.
(c) Discretionary appropriations For the budget year and each outyear, the baseline shall be calculated using the following assumptions regarding all amounts other than those covered by subsection (b):
Rest of § 907 unchanged ·
5 U.S.C. § 8902 Contracting authority
1 change the bill asks for here, 1 carried out
- Carried out:
Section 8902 of title 5, United States Code, is amended by adding at the end the following new subsections:
(p) A contract may not be made or a plan approved under this chapter under which a carrier has an agreement with a pharmacy benefits manager (in this subsection referred to as a “PBM”) to manage prescription drug coverage or to control the costs of the prescription drug coverage …
The section already has a provision under this letter or number, so it would have two.
This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.
§ 8902(o)–(q)
Start of § 8902 to (n)(2) unchanged ·
(o) A contract may not be made or a plan approved which includes coverage for any benefit, item, or service for which funds may not be used under the Assisted Suicide Funding Restriction Act of 1997.
(p) Each contract under this chapter shall require the carrier to comply with requirements described in the provisions of sections 2799A–1, 2799A–2, and 2799A–7 of the Public Health Service Act, sections 716, 717, and 722 of the Employee Retirement Income Security Act of 1974, and sections 9816, 9817, and 9822 of the Internal Revenue Code of 1986 (as applicable) in the same manner as such provisions apply to a group health plan or health insurance issuer offering group or individual health insurance coverage, as described in such sections. The provisions of sections 2799B–1, 2799B–2, 2799B–3, and 2799B–5 of the Public Health Service Act shall apply to a health care provider and facility and an air ambulance provider described in such respective sections with respect to an enrollee in a health benefits plan under this chapter in the same manner as such provisions apply to such a provider and facility with respect to an enrollee in a group health plan or group or individual health insurance coverage offered by a health insurance issuer, as described in such sections.
(p) [inserted: A contract may not be made or a plan approved under this chapter under which a carrier has an agreement with a pharmacy benefits manager (in this subsection referred to as a “PBM”) to manage prescription drug coverage or to control the costs of the prescription drug coverage unless the carrier and PBM adhere to the following criteria:]
(1) [inserted: The PBM may not transmit any personally identifiable utilization, protected health information, or claims data with respect to an individual enrolled under such contract or plan to a pharmacy owned by the PBM if the individual has not voluntarily elected in writing or via secure electronic means to fill that particular prescription at such a pharmacy.]
(2) [inserted: The PBM may not require that an individual enrolled under such contract or plan use a retail pharmacy, mail order pharmacy, specialty pharmacy, or other pharmacy entity providing pharmacy services in which the PBM has an ownership interest or that has an ownership interest in the PBM or provide an incentive to a plan enrollee to encourage the enrollee to use a retail pharmacy, mail order pharmacy, specialty pharmacy, or other pharmacy entity providing pharmacy services in which the PBM has an ownership interest or that has an ownership interest in the PBM, if the incentive is applicable only to such pharmacies.]
(q)
(1) [inserted: If a contract made or plan approved under this chapter provides for a standard for reimbursement (as described in paragraph (2)) with respect to a prescription drug plan, such contract or plan shall provide that the applicable carrier—]
(A) [inserted: update such standard not less frequently than once every 7 days, beginning with an initial update on January 1 of each year, to accurately reflect the market price of acquiring the drug;]
(B) [inserted: disclose to applicable pharmacies and the contracting entities of such pharmacies the sources used for making any such update immediately without requirement of request;]
(C) [inserted: if the source for such a standard for reimbursement is not publicly available, disclose to the applicable pharmacies and contracting entities of such pharmacies all individual drug prices to be so updated in advance of the use of such prices for the reimbursement of claims;]
(D) [inserted: establish a process to appeal, investigate, and resolve disputes regarding individual drug prices that are less than the pharmacy acquisition price for such drug, which must be adjudicated within 7 days of the pharmacy filing its appeal; and]
(E) [inserted: provide all such pricing data in an .xml spreadsheet format or a comparable easily accessible and complete spreadsheet format.]
(2) [inserted: For purposes of paragraph (1), a standard for reimbursement of a pharmacy is any methodology or formula for varying the pricing of a drug or drugs during the term of the pharmacy reimbursement contract that is based on the cost of the drug involved, including drug pricing references and amounts that are based upon average wholesale price, wholesale average cost, average manufacturer price, average sales price, maximum allowable cost, or other costs, whether publicly available or not.]
5 U.S.C. § 8905 Election of coverage
2 changes the bill asks for here, 2 carried out
- Carried out:
in the matter preceding paragraph (1), by striking
An
and insertingConsistent with the last sentence of this subsection, an
; and - Carried out:
by adding at the end the following:
. An individual who is entitled to benefits under part A of title XVIII of the Social Security Act (42 U.S.C. 1395c et seq.) by reason of section 226 or 226A of such Act (42 U.S.C. 426, 426–1), or otherwise eligible to enroll under such part pursuant to section 1818 or 1818A of such Act (42 U.S.C. 1395i–2, 1395i–2a), and who first becomes an annuitant after the date of enactment of this sentence may not continue enrollment in any health benefits plan under this chapter.
.
§ 8905(a)–(b)
Start of § 8905 to (a)(2) unchanged ·
(3) for self and family.
(b) [struck: An][inserted: Consistent] [inserted: with the last sentence of this subsection, an ]annuitant who at the time he becomes an annuitant was enrolled in a health benefits plan under this chapter—
(1) as an employee for a period of not less than—
(A) the 5 years of service immediately before retirement;
§ 8905(b)–(c)
(b)(1)(B)–(C) unchanged ·
whichever is shortest; or
(2) as a member of the family of an employee or annuitant;
may continue his enrollment under the conditions of eligibility prescribed by regulations of the Office. The Office may, in its sole discretion, waive the requirements of this subsection in the case of an individual who fails to satisfy such requirements if the Office determines that, due to exceptional circumstances, it would be against equity and good conscience not to allow such individual to be enrolled as an annuitant in a health benefits plan under this chapter[inserted: . An individual who is entitled to benefits under part A of title XVIII of the Social Security Act (42 U.S.C. 1395c et seq.) by reason of section 226 or 226A of such Act (42 U.S.C. 426, 426–1), or otherwise eligible to enroll under such part pursuant to section 1818 or 1818A of such Act (42 U.S.C. 1395i–2, 1395i–2a), and who first becomes an annuitant after the date of enactment of this sentence may not continue enrollment in any health benefits plan under this chapter.]
(c)
(1) A former spouse may—
Rest of § 8905 unchanged ·
10 U.S.C. § 1074g Pharmacy benefits program
1 change the bill asks for here, 1 carried out
- Carried out:
Section 1074g(d) of title 10, United States Code, is amended by adding at the end the following new paragraph:
(3) To the extent practicable, with respect to the TRICARE retail pharmacy program described in subsection (a)(2)(E)(ii), the Secretary shall ensure that a contract entered into with a TRICARE managed care support contractor includes requirements described in section …
The section already has a provision under this letter or number, so it would have two.
This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.
§ 1074g(d)–(f)
Start of § 1074g to (d)(1) unchanged ·
(2) The Secretary shall use a modification to the bid price adjustment methodology in the managed care support contracts current as of October 5, 1999, to ensure equitable and timely reimbursement to the TRICARE managed care support contractors for pharmaceutical products delivered in the nonmilitary environments. The methodology shall take into account the “at-risk” nature of the contracts as well as managed care support contractor pharmacy costs attributable to changes to pharmacy service or formulary management at military medical treatment facilities, and other military activities and policies that affect costs of pharmacy benefits provided through the Civilian Health and Medical Program of the Uniformed Services. The methodology shall also account for military treatment facility costs attributable to the delivery of pharmaceutical products in the military facility environment which were prescribed by a network provider.
(3) With respect to the TRICARE retail pharmacy program described in subsection (a)(2)(E)(ii), the Secretary shall ensure that a contract entered into with a TRICARE pharmacy program contractor includes requirements described in section 1860D–12(b)(6) of the Social Security Act (42 U.S.C. 1395w–112(b)(6)) to ensure the provision of information regarding the pricing standard for prescription drugs.
(3) [inserted: To the extent practicable, with respect to the TRICARE retail pharmacy program described in subsection (a)(2)(E)(ii), the Secretary shall ensure that a contract entered into with a TRICARE managed care support contractor includes requirements described in section 1860D–12(b)(6) of the Social Security Act (42 U.S.C. 1395w–112(b)(6)) to ensure the provision of information regarding the pricing standard for prescription drugs.]
(e) Pharmacy Data Transaction Service.— The Secretary of Defense shall implement the use of the Pharmacy Data Transaction Service in all fixed facilities of the uniformed services under the jurisdiction of the Secretary, in the TRICARE retail pharmacy program, and in the national mail-order pharmacy program.
(f) Procurement of Pharmaceuticals by TRICARE Retail Pharmacy Program.— With respect to any prescription filled after January 28, 2008, the TRICARE retail pharmacy program shall be treated as an element of the Department of Defense for purposes of the procurement of drugs by Federal agencies under section 8126 of title 38 to the extent necessary to ensure that pharmaceuticals paid for by the Department of Defense that are provided by pharmacies under the program to eligible covered beneficiaries under this section are subject to the pricing standards in such section 8126.
Rest of § 1074g unchanged ·
11 U.S.C. § 522 Exemptions
1 change the bill asks for here, 1 carried out
- Carried out:
Section 522 of title 11, United States Code, is amended by adding at the end the following new subsection:
(r) For purposes of this section, any health savings account (as described in section 223 of the Internal Revenue Code of 1986) shall be treated in the same manner as an individual retirement account described in section 408 of such Code..
§ 522(q)–(r)
Start of § 522 to (q)(1)(B)(iii) unchanged ·
(iv) any criminal act, intentional tort, or willful or reckless misconduct that caused serious physical injury or death to another individual in the preceding 5 years.
(2) Paragraph (1) shall not apply to the extent the amount of an interest in property described in subparagraphs (A), (B), (C), and (D) of subsection (p)(1) is reasonably necessary for the support of the debtor and any dependent of the debtor.
(r) [inserted: For purposes of this section, any health savings account (as described in section 223 of the Internal Revenue Code of 1986) shall be treated in the same manner as an individual retirement account described in section 408 of such Code.]
15 U.S.C. § 44 Definitions
3 changes the bill asks for here, 2 carried out
- Not carried out:
Section 4 of the Federal Trade Commission Act (15 U.S.C. 44) is amended, in the undesignated paragraph relating to the definition of the term Corporation—
We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: in the undesignated paragraph relating to the definition of the term corporation — - Carried out:
by striking
, and any
and inserting, any
; and - Carried out:
by inserting before the period at the end the following:
, and any organization described in section 501(c)(3) of the Internal Revenue Code of 1986 that is exempt from taxation under section 501(a) of such Code
.
§ 44
§ 44. Definitions
The words defined in this section shall have the following meaning when found in this subchapter, to wit:
“Commerce” means commerce among the several States or with foreign nations, or in any Territory of the United States or in the District of Columbia, or between any such Territory and another, or between any such Territory and any State or foreign nation, or between the District of Columbia and any State or Territory or foreign nation.
“Corporation” shall be deemed to include any company, trust, so-called Massachusetts trust, or association, incorporated or unincorporated, which is organized to carry on business for its own profit or that of its members, and has shares of capital or capital stock or certificates of interest, [struck: and ]any company, trust, so-called Massachusetts trust, or association, incorporated or unincorporated, without shares of capital or capital stock or certificates of interest, except partnerships, which is organized to carry on business for its own profit or that of its members.
“Documentary evidence” includes all documents, papers, correspondence, books of account, and financial and corporate records.
“Acts to regulate commerce” means subtitle IV of title 49 and the Communications Act of 1934 [47 U.S.C. 151 et seq.] and all Acts amendatory thereof and supplementary thereto.
“Antitrust Acts” means the Act entitled “An Act to protect trade and commerce against unlawful restraints and monopolies”, approved July 2, 1890; also sections 73 to 76, inclusive, of an Act entitled “An Act to reduce taxation, to provide revenue for the Government, and for other purposes”, approved August 27, 1894; also the Act entitled “An Act to amend sections 73 and 76 of the Act of August 27, 1894, entitled ‘An Act to reduce taxation, to provide revenue for the Government, and for other purposes’ ”, approved February 12, 1913; and also the Act entitled “An Act to supplement existing laws against unlawful restraints and monopolies, and for other purposes”, approved October 15, 1914.
“Banks” means the types of banks and other financial institutions referred to in section 57a(f)(2) of this title.
“Foreign law enforcement agency” means—
(1) any agency or judicial authority of a foreign government, including a foreign state, a political subdivision of a foreign state, or a multinational organization constituted by and comprised of foreign states, that is vested with law enforcement or investigative authority in civil, criminal, or administrative matters; and
(2) any multinational organization, to the extent that it is acting on behalf of an entity described in paragraph (1)[inserted: , and any organization described in section 501(c)(3) of the Internal Revenue Code of 1986 that is exempt from taxation under section 501(a) of such Code].
21 U.S.C. § 355 New drugs
24 changes the bill asks for here, 22 carried out
- Carried out:
in subclause (I), by striking
180 days after the date
and all that follows throughby any first applicant
and inserting180 days after the earlier of the dates described in items (aa) and (bb) of subclause (II)
; - Carried out:
by redesignating subclause (II) as subclause (III); and
- Carried out:
by inserting after subclause (I) the following:
(II) Dates described.— (aa) First date.— The date described in this item is the date of the first commercial marketing of the drug (including the commercial marketing of the listed drug) by any first applicant. (bb) Second date.— The date described in this item is the date on …
- Carried out:
in subparagraph (A)(i), by inserting
, 10.31,
after10.30
; - Carried out:
by striking
application and
and insertingapplication or
; - Carried out:
by striking If the Secretary and inserting the following:(i) In general.— If the Secretary;
- Not carried out:
by striking the second sentence and inserting the following:
(ii) Primary purpose of delaying.— (I) In general.— In determining whether a petition was submitted with the primary purpose of delaying an application, the Secretary may consider the following factors: (aa) Whether the petition was submitted in accordance with paragraph (2)(B), …
We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: striking the second sentence and inserting the following: QCONTENT; and - Carried out:
by adding at the end the following:
(iii) Referral to the Federal Trade Commission.— The Secretary shall establish procedures for referring to the Federal Trade Commission any petition or supplement to a petition that the Secretary determines was submitted with the primary purpose of delaying approval of an …
- Carried out:
by striking subparagraph (F);
- Carried out:
by redesignating subparagraphs (G) through (I) as subparagraphs (F) through (H), respectively; and
- Carried out:
in subparagraph (H), as so redesignated, by striking
submission of this petition
and insertingsubmission of this document
; - Carried out:
by redesignating subparagraphs (A) through (C) as subparagraphs (C) through (E), respectively;
- Carried out:
by inserting before subparagraph (C), as so redesignated, the following:
(A) In general.— A person shall submit a petition to the Secretary under paragraph (1) before filing a civil action in which the person seeks to set aside, delay, rescind, withdraw, or prevent submission, review, or approval of an application submitted under subsection (b)(2) or …
- Carried out:
in the heading, by striking
within 150 days
; - Carried out:
in clause (i), by striking
during the 150-day period referred to in paragraph (1)(F),
; and - Carried out:
by amending clause (ii) to read as follows:
(ii) on or after the date that is 151 days after the date of submission of the petition, the Secretary approves or has approved the application that is the subject of the petition without having made such a final decision.;
- Carried out:
by amending subparagraph (D), as so redesignated, to read as follows:
(D) Dismissal of certain civil actions.— (i) Petition.— If a person files a civil action against the Secretary in which a person seeks to set aside, delay, rescind, withdraw, or prevent submission, review, or approval of an application submitted under subsection (b)(2) or (j) of …
- Carried out:
in clause (iii) of subparagraph (E), as so redesignated, by striking
as defined under subparagraph (2)(A)
and insertingwithin the meaning of subparagraph (C)
; and - Not carried out:
by striking
Exceptions
and all that follows throughThis subsection does
and insertingExceptions.—This subsection does
;“Exceptions” isn't in § 355(q)(4) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“Exceptions” not found in /us/usc/t21/s355/q/4 - Carried out:
by striking subparagraph (B); and
- Carried out:
by redesignating clauses (i) and (ii) as subparagraphs (A) and (B), respectively, and adjusting the margins accordingly.
- Carried out:
Section 505(a) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(a)) is amended by inserting
, or there is in effect a conditional approval under section 524C with respect to such drug
before the period.
- Carried out:
Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) is amended by adding at the end the following:
(aa) Prompt Approval of Drugs When safety information Is Added to Labeling.— (1) General rule.— A drug for which an application has been submitted or approved under subsection (b)(2) or (j) shall not be considered ineligible for approval under this section or misbranded under …
- Carried out:
Section 505(a) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(a)) is amended by inserting
, or there is in effect a provisional approval under section 524B with respect to such drug
before the period.
§ 355(a)–(b)
§ 355. New drugs
(a) Necessity of effective approval of application No person shall introduce or deliver for introduction into interstate commerce any new drug, unless an approval of an application filed pursuant to subsection (b) or (j) is effective with respect to such drug[inserted: , or there is in effect a conditional approval under section 524C with respect to such drug, or there is in effect a provisional approval under section 524B with respect to such drug].
(b) Filing application; contents
(1)
(A) Any person may file with the Secretary an application with respect to any drug subject to the provisions of subsection (a). Such persons shall submit to the Secretary as part of the application—
§ 355(j)(5)(B)The approval of an application submitted under paragraph (2) shall be made…(iii)–(v)
(b)(1)(A)(i)–(j)(5)(B)(iii) unchanged ·
In such an action, each of the parties shall reasonably cooperate in expediting the action.
(iv) 180-day exclusivity period.—
(I) Effectiveness of application.— Subject to subparagraph (D), if the application contains a certification described in paragraph (2)(A)(vii)(IV) and is for a drug for which a first applicant has submitted an application containing such a certification, the application shall be made effective on the date that is 180 days after the [struck: date][inserted: earlier] of the [struck: first][inserted: dates] [struck: commercial][inserted: described] [struck: marketing][inserted: in] [struck: of][inserted: items] [struck: the][inserted: (aa)] [struck: drug][inserted: and] ([struck: including][inserted: bb)] [struck: the commercial marketing ]of [struck: the][inserted: subclause] [struck: listed drug][inserted: (II])[struck: by any first applicant].
(II) [inserted: Dates described.—]
(aa) [inserted: First date.—] [inserted: The date described in this item is the date of the first commercial marketing of the drug (including the commercial marketing of the listed drug) by any first applicant.]
(bb) [inserted: Second date.—] [inserted: The date described in this item is the date on which all of the following conditions are first met, provided no application submitted by any first applicant is approved on or before such date:]
(AA) [inserted: An application for the drug submitted by an applicant other than a first applicant has received tentative approval and could receive approval, if no first applicant were eligible for 180-day exclusivity under this clause, and such applicant has not entered into an agreement that would prevent commercial marketing upon approval and has submitted a notification to the Secretary documenting that it has not entered into an agreement that would prevent commercial marketing.]
(BB) [inserted: Thirty-three months have passed since the date of submission of an application for the drug by one first applicant, if there is only one first applicant, or, in the case of more than one first applicant, 33 months have passed since the date of submission of all such applications.]
(CC) [inserted: Approval of an application for the drug submitted by at least one first applicant would not be precluded under clause (iii).]
[struck: (II)] [inserted: (III)] Definitions.— In this paragraph:
(aa) 180-day exclusivity period.— The term “180-day exclusivity period” means the 180-day period ending on the day before the date on which an application submitted by an applicant other than a first applicant could become effective under this clause.
(bb) First applicant.— As used in this subsection, the term “first applicant” means an applicant that, on the first day on which a substantially complete application containing a certification described in paragraph (2)(A)(vii)(IV) is submitted for approval of a drug, submits a substantially complete application that contains and lawfully maintains a certification described in paragraph (2)(A)(vii)(IV) for the drug.
(cc) Substantially complete application.— As used in this subsection, the term “substantially complete application” means an application under this subsection that on its face is sufficiently complete to permit a substantive review and contains all the information required by paragraph (2)(A).
(dd) Tentative approval.—
(AA) In general.— The term “tentative approval” means notification to an applicant by the Secretary that an application under this subsection meets the requirements of paragraph (2)(A), but cannot receive effective approval because the application does not meet the requirements of this subparagraph, there is a period of exclusivity for the listed drug under subparagraph (F) or section 355a of this title, or there is a 7-year period of exclusivity for the listed drug under section 360cc of this title.
(BB) Limitation.— A drug that is granted tentative approval by the Secretary is not an approved drug and shall not have an effective approval until the Secretary issues an approval after any necessary additional review of the application.
(v) 180-day exclusivity period for competitive generic therapies.—
(I) Effectiveness of application.— Subject to subparagraph (D)(iv), if the application is for a drug that is the same as a competitive generic therapy for which any first approved applicant has commenced commercial marketing, the application shall be made effective on the date that is 180 days after the date of the first commercial marketing of the competitive generic therapy (including the commercial marketing of the listed drug) by any first approved applicant.
§ 355(q)(1)(A)Determination(i)–(ii)
(j)(5)(B)(v)(II)–(q)(1) unchanged ·
(A) Determination The Secretary shall not delay approval of a pending application submitted under subsection (b)(2) or (j) of this section or section 262(k) of title 42 because of any request to take any form of action relating to the application, either before or during consideration of the request, unless—
(i) the request is in writing and is a petition submitted to the Secretary pursuant to section 10.30[inserted: ,] [inserted: 10.31, ]or 10.35 of title 21, Code of Federal Regulations (or any successor regulations); and
(ii) the Secretary determines, upon reviewing the petition, that a delay is necessary to protect the public health.
Consideration of the petition shall be separate and apart from review and approval of any application.
§ 355(q)Petitions and civil actions regarding approval of certain applications(1)–(3)
(q)(1)(B)–(C) unchanged ·
(D) Public disclosure Any information conveyed by the Secretary under subparagraph (C) shall be considered part of the application and shall be subject to the disclosure requirements applicable to information in such application.
(E) Denial based on intent to delay
(i) [inserted: In general.—] [inserted: If the Secretary determines that a petition or a supplement to the petition was submitted with the primary purpose of delaying the approval of an application or the petition does not on its face raise valid scientific or regulatory issues, the Secretary may deny the petition at any point based on such determination. The Secretary may issue guidance to describe the factors that will be used to determine under this subparagraph whether a petition is submitted with the primary purpose of delaying the approval of an application.]
(iii) [inserted: Referral to the Federal Trade Commission.—] [inserted: The Secretary shall establish procedures for referring to the Federal Trade Commission any petition or supplement to a petition that the Secretary determines was submitted with the primary purpose of delaying approval of an application. Such procedures shall include notification to the petitioner by the Secretary.]
[struck: If the Secretary determines that a petition or a supplement to the petition was submitted with the primary purpose of delaying the approval of an application and the petition does not on its face raise valid scientific or regulatory issues, the Secretary may deny the petition at any point based on such determination. The Secretary may issue guidance to describe the factors that will be used to determine under this subparagraph whether a petition is submitted with the primary purpose of delaying the approval of an application.]
[struck: (F)] [struck: Final agency action] [struck: The Secretary shall take final agency action on a petition not later than 150 days after the date on which the petition is submitted. The Secretary shall not extend such period for any reason, including—]
[struck: (i)] [struck: any determination made under subparagraph (A);]
[struck: (ii)] [struck: the submission of comments relating to the petition or supplemental information supplied by the petitioner; or]
[struck: (iii)] [struck: the consent of the petitioner.]
[struck: (G)] [inserted: (F)] Extension of 30-month period If the filing of an application resulted in first-applicant status under subsection (j)(5)(D)(i)(IV) and approval of the application was delayed because of a petition, the 30-month period under such subsection is deemed to be extended by a period of time equal to the period beginning on the date on which the Secretary received the petition and ending on the date of final agency action on the petition (inclusive of such beginning and ending dates), without regard to whether the Secretary grants, in whole or in part, or denies, in whole or in part, the petition.
[struck: (H)] [inserted: (G)] Certification The Secretary shall not consider a petition for review unless the party submitting such petition does so in written form and the subject document is signed and contains the following certification: “I certify that, to my best knowledge and belief: (a) this petition includes all information and views upon which the petition relies; (b) this petition includes representative data and/or information known to the petitioner which are unfavorable to the petition; and (c) I have taken reasonable steps to ensure that any representative data and/or information which are unfavorable to the petition were disclosed to me. I further certify that the information upon which I have based the action requested herein first became known to the party on whose behalf this petition is submitted on or about the following date: __________. If I received or expect to receive payments, including cash and other forms of consideration, to file this information or its contents, I received or expect to receive those payments from the following persons or organizations: _____________. I verify under penalty of perjury that the foregoing is true and correct as of the date of the submission of this petition.”, with the date on which such information first became known to such party and the names of such persons or organizations inserted in the first and second blank space, respectively.
[struck: (I)] [inserted: (H)] Verification The Secretary shall not accept for review any supplemental information or comments on a petition unless the party submitting such information or comments does so in written form and the subject document is signed and contains the following verification: “I certify that, to my best knowledge and belief: (a) I have not intentionally delayed submission of this document or its contents; and (b) the information upon which I have based the action requested herein first became known to me on or about __________. If I received or expect to receive payments, including cash and other forms of consideration, to file this information or its contents, I received or expect to receive those payments from the following persons or organizations: _____. I verify under penalty of perjury that the foregoing is true and correct as of the date of the submission of this [struck: petition][inserted: document].”, with the date on which such information first became known to the party and the names of such persons or organizations inserted in the first and second blank space, respectively.
(2) Exhaustion of administrative remedies
(A) [inserted: In general.—] [inserted: A person shall submit a petition to the Secretary under paragraph (1) before filing a civil action in which the person seeks to set aside, delay, rescind, withdraw, or prevent submission, review, or approval of an application submitted under subsection (b)(2) or (j) of this section or section 351(k) of the Public Health Service Act. Such petition and any supplement to such a petition shall describe all information and arguments that form the basis of the relief requested in any civil action described in the previous sentence.]
(B) [inserted: Timely submission of citizen petition.—] [inserted: A petition and any supplement to a petition shall be submitted not later than 60 days after the date on which the person first knew, or reasonably should have known, the information that forms the basis of the request made in the petition or supplement.]
[struck: (A)] [inserted: (C)] Final agency action[struck: within 150 days] The Secretary shall be considered to have taken final agency action on a petition if—
(i) [struck: during ]the [struck: 150-day period referred to in paragraph (1)(F), the ]Secretary makes a final decision within the meaning of section 10.45(d) of title 21, Code of Federal Regulations (or any successor regulation); or
(ii) [struck: such][inserted: on] [struck: period][inserted: or] [struck: expires][inserted: after] [struck: without][inserted: the] [inserted: date that is 151 days after ]the [inserted: date of submission of the petition, the ]Secretary [inserted: approves or has approved the application that is the subject of the petition without ]having made such a final decision.
[struck: (B)] [inserted: (D)] Dismissal of certain civil actions[inserted: .—]
(i) [inserted: Petition.—] [inserted: If a person files a civil action against the Secretary in which a person seeks to set aside, delay, rescind, withdraw, or prevent submission, review, or approval of an application submitted under subsection (b)(2) or (j) of this section or section 351(k) of the Public Health Service Act without complying with the requirements of subparagraph (A), the court shall dismiss without prejudice the action for failure to exhaust administrative remedies.]
(ii) [inserted: Timeliness.—] [inserted: If a person files a civil action against the Secretary in which a person seeks to set aside, delay, rescind, withdraw, or prevent submission, review, or approval of an application submitted under subsection (b)(2) or (j) of this section or section 351(k) of the Public Health Service Act without complying with the requirements of subparagraph (B), the court shall dismiss with prejudice the action for failure to timely file a petition.]
(iii) [inserted: Final response.—] [inserted: If a civil action is filed against the Secretary with respect to any issue raised in a petition timely filed under paragraph (1) in which the petitioner requests that the Secretary take any form of action that could, if taken, set aside, delay, rescind, withdraw, or prevent submission, review, or approval of an application submitted under subsection (b)(2) or (j) of this section or section 351(k) of the Public Health Service Act before the Secretary has taken final agency action on the petition within the meaning of subparagraph (C), the court shall dismiss without prejudice the action for failure to exhaust administrative remedies.]
[struck: If a civil action is filed against the Secretary with respect to any issue raised in the petition before the Secretary has taken final agency action on the petition within the meaning of subparagraph (A), the court shall dismiss without prejudice the action for failure to exhaust administrative remedies.]
[struck: (C)] [inserted: (E)] Administrative record For purposes of judicial review related to the approval of an application for which a petition under paragraph (1) was submitted, the administrative record regarding any issue raised by the petition shall include—
(i) the petition filed under paragraph (1) and any supplements and comments thereto;
(ii) the Secretary’s response to such petition, if issued; and
(iii) other information, as designated by the Secretary, related to the Secretary’s determinations regarding the issues raised in such petition, as long as the information was considered by the agency no later than the date of final agency action [struck: as][inserted: within] [struck: defined][inserted: the] [struck: under][inserted: meaning] [inserted: of ]subparagraph ([struck: 2][inserted: C])[struck: (A)], and regardless of whether the Secretary responded to the petition at or before the approval of the application at issue in the petition.
(3) Annual report on delays in approvals per petitions The Secretary shall annually submit to the Congress a report that specifies—
(A) the number of applications that were approved during the preceding 12-month period;
§ 355(q)Petitions and civil actions regarding approval of certain applications(4)–(5)
(q)(3)(B)–(D) unchanged ·
(4) Exceptions
(A) This subsection does not apply to—
[struck: (i)] [inserted: (A)] a petition that relates solely to the timing of the approval of an application pursuant to subsection (j)(5)(B)(iv); or
[struck: (ii)] [inserted: (B)] a petition that is made by the sponsor of an application and that seeks only to have the Secretary take or refrain from taking any form of action with respect to that application.
[struck: (B)] [struck: Paragraph (2) does not apply to a petition addressing issues concerning an application submitted pursuant to section 262(k) of title 42.]
(5) Definitions
(A) Application For purposes of this subsection, the term “application” means an application submitted under subsection (b)(2) or (j) of this section or section 262(k) of title 42.
§ 355(z)–(aa)
(q)(5)(B)–(z)(4)(A) unchanged ·
(B) The Secretary shall issue a written response granting or denying a request from a sponsor for a waiver within 60 days of receiving such request.
(5) No diversity action plan shall be required for a submission described in section 360bbb of this title.
(aa) [inserted: Prompt Approval of Drugs When safety information Is Added to Labeling.—]
(1) [inserted: General rule.—] [inserted: A drug for which an application has been submitted or approved under subsection (b)(2) or (j) shall not be considered ineligible for approval under this section or misbranded under section 502 on the basis that the labeling of the drug omits safety information, including contraindications, warnings, precautions, dosing, administration, or other information pertaining to safety, when the omitted safety information is protected by exclusivity under clause (iii) or (iv) of subsection (j)(5)(F), clause (iii) or (iv) of subsection (c)(3)(E), or section 527(a), or by an extension of such exclusivity under section 505A or 505E.]
(2) [inserted: Labeling.—] [inserted: Notwithstanding clauses (iii) and (iv) of subsection (j)(5)(F), clauses (iii) and (iv) of subsection (c)(3)(E), or section 527, the Secretary shall require that the labeling of a drug approved pursuant to an application submitted under subsection (b)(2) or (j) that omits safety information described in paragraph (1) include a statement of any appropriate safety information that the Secretary considers necessary to ensure safe use.]
(3) [inserted: Availability and scope of exclusivity.—] [inserted: This subsection does not affect—]
(A) [inserted: the availability or scope of exclusivity or an extension of exclusivity described in subparagraph (A) or (B) of section 505A(o)(3);]
(B) [inserted: the question of the eligibility for approval under this section of any application described in subsection (b)(2) or (j) that omits any other aspect of labeling protected by exclusivity under—]
(i) [inserted: clause (iii) or (iv) of subsection (j)(5)(F);]
(ii) [inserted: clause (iii) or (iv) of subsection (c)(3)(E); or]
(iii) [inserted: section 527(a); or]
(C) [inserted: except as expressly provided in paragraphs (1) and (2), the operation of this section or section 527.]
21 U.S.C. § 355c Research into pediatric uses for drugs and biological products
1 change the bill asks for here, 1 carried out
- Carried out:
Section 505B(l) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355c(l)) is amended to read as follows:
(l) Biosimilar biological products.— A biological product for which an application is submitted under section 351(k) of the Public Health Service Act shall be considered to have a new active ingredient for purposes of this section, except that a pediatric assessment shall not be …
§ 355c(k)–(m)
Start of § 355c to (k) unchanged ·
(1) In general; exemption for orphan indications Unless the Secretary requires otherwise by regulation and except as provided in paragraph (2), this section does not apply to any drug or biological product for an indication for which orphan designation has been granted under section 360bb of this title.
(2) Applicability despite orphan designation of certain indications This section shall apply with respect to a drug or biological product for which an indication has been granted orphan designation under 360bb3 of this title if the investigation described in subsection (a)(3) applies to the drug or biological product as described in subsection (a)(1)(B).
(l) [struck: New][inserted: Biosimilar] [struck: active][inserted: biological] [struck: ingredient][inserted: products.—] [inserted: A biological product for which an application is submitted under section 351(k) of the Public Health Service Act shall be considered to have a new active ingredient for purposes of this section, except that a pediatric assessment shall not be required for a claimed indication in a relevant pediatric population if the assessment would involve—]
(1) [struck: Non-interchangeable biosimilar biological product] [struck: A biological product that is biosimilar to ]a [struck: reference][inserted: condition] [struck: product under section 262 ]of [struck: title][inserted: use] [struck: 42, and ]that [struck: the Secretary ]has not [struck: determined][inserted: been] [struck: to][inserted: previously] [struck: meet][inserted: approved] [struck: the standards described in subsection (k)(4) of such section ]for [struck: interchangeability with ]the reference product[struck: ,][inserted: ;] [struck: shall be considered to have a new active ingredient under this section.][inserted: or]
(2) [struck: Interchangeable biosimilar biological product] [struck: A biological product that is interchangeable with ]a [struck: reference][inserted: dosage] [struck: product][inserted: form,] [struck: under][inserted: strength,] [struck: section][inserted: or] [struck: 262][inserted: route] of [struck: title][inserted: administration] [struck: 42][inserted: that] [struck: shall][inserted: differs] [struck: not][inserted: from] [struck: be][inserted: that] [struck: considered][inserted: of] [struck: to][inserted: the] [struck: have][inserted: reference] [struck: a new active ingredient under this section][inserted: product].
(m) List of primary molecular targets
(1) In general Within one year of August 18, 2017, the Secretary shall establish and update regularly, and shall publish on the internet website of the Food and Drug Administration—
Rest of § 355c unchanged ·
21 U.S.C. § 356 Expedited approval of drugs for serious or life-threatening diseases or conditions
1 change the bill asks for here, 1 carried out
- Carried out:
Subsection (b) of section 506 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356) is amended by adding at the end the following:
(4) Unmet medical need.— For purposes of paragraph (1), a drug to address an unmet medical need for a disease or condition shall be deemed to address such medical need if fewer than 3 available drugs exist for the treatment of such disease or condition..
§ 356(b)–(c)
Start of § 356 to (b)(1) unchanged ·
(2) Request for designation The sponsor of a new drug may request the Secretary to designate the drug as a fast track product. A request for the designation may be made concurrently with, or at any time after, submission of an application for the investigation of the drug under section 355(i) of this title or section 351(a)(3) of the Public Health Service Act [42 U.S.C. 262(a)(3)].
(3) Designation Within 60 calendar days after the receipt of a request under paragraph (2), the Secretary shall determine whether the drug that is the subject of the request meets the criteria described in paragraph (1). If the Secretary finds that the drug meets the criteria, the Secretary shall designate the drug as a fast track product and shall take such actions as are appropriate to expedite the development and review of the application for approval of such product.
(4) [inserted: Unmet medical need.—] [inserted: For purposes of paragraph (1), a drug to address an unmet medical need for a disease or condition shall be deemed to address such medical need if fewer than 3 available drugs exist for the treatment of such disease or condition.]
(c) Accelerated approval of a drug for a serious or life-threatening disease or condition, including a fast track product
(1) In general
(A) Accelerated approval The Secretary may approve an application for approval of a product for a serious or life-threatening disease or condition, including a fast track product, under section 355(c) of this title or section 351(a) of the Public Health Service Act [42 U.S.C. 262(a)] upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. The approval described in the preceding sentence is referred to in this section as “accelerated approval”.
Rest of § 356 unchanged ·
21 U.S.C. § 360cc Protection for drugs for rare diseases or conditions
6 changes the bill asks for here, 3 carried out
- Carried out:
Section 527(a) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360cc(a)) is amended to read as follows:
(a) Exclusivity.— (1) In general.— Except as provided in subsection (b), if the Secretary approves an application filed pursuant to section 505, or issues a license under section 351 of the Public Health Service Act, for a drug designated under section 526 for a rare disease or …
- Carried out:
Section 505(j)(5)(B)(iv)(II)(dd)(AA) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360cc) is amended by striking
7-year period
and insertingperiod
. - Not carried out:
Section 505A(b)(1)(A)(ii) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360cc) is amended by striking
rather than seven years;
and inserting, or three years and six months, rather than seven years or three years, respectively;
.“rather than seven years;” isn't in § 360cc in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“rather than seven years;” not found in /us/usc/t21/s360cc - Not carried out:
Section 505A(c)(1)(A)(ii) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360cc) is amended by striking
rather than seven years;
and inserting, or three years and six months, rather than seven years or three years, respectively;
.“rather than seven years;” isn't in § 360cc in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“rather than seven years;” not found in /us/usc/t21/s360cc - Not carried out:
Section 505E(a) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360cc) is amended by striking
7-year period
and insertingexclusivity periods
.“7-year period” isn't in § 360cc(a) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“7-year period” not found in /us/usc/t21/s360cc/a - Carried out:
Section 527(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360cc) is amended by striking
the 7-year period
and insertingany exclusivity period
.
§ 360cc(a)–(b)
§ 360cc. Protection for drugs for rare diseases or conditions
(a) [struck: Exclusive approval, certification, or license][inserted: Exclusivity.—] [struck: Except as provided in subsection (b), if the Secretary—]
(1) [inserted: In general.—] [inserted: Except as provided in subsection (b), if the Secretary ]approves an application filed pursuant to section [struck: 355][inserted: 505,] [inserted: or issues a license under section 351 ]of [struck: this][inserted: the] [struck: title][inserted: Public Health Service Act], [inserted: for a drug designated under section 526 for a rare disease ]or[inserted: condition, the Secretary may not approve an application filed pursuant to section 505, or issue a license under section 351 of the Public Health Service Act, for the same drug for the same disease or condition for a person who is not the holder of such approved application or of such license until the expiration of the exclusivity period described in paragraph (2).]
(2) [inserted: Exclusivity period described.—] [inserted: The exclusivity period described in this paragraph, with respect to a drug designated under section 526 for a rare disease or condition, is—]
(A) [inserted: a single period of exclusivity with respect to the first designation of such drug under such section for that rare disease or condition; or]
(B) [inserted: in the case of a drug that has previously received a period of exclusivity under paragraph (1), a single 3-year period of exclusivity with respect to any subsequent designation of such drug under such section for any other rare disease or condition.]
(3) [inserted: Limitation.—] [inserted: In the case of a drug that has received two periods of exclusivity pursuant to paragraph (1), no additional exclusivity period under this section is available with respect to such drug, regardless of whether such drug has been designated under section 526 for a rare disease or condition that is distinct from the rare disease or condition for which such exclusivity periods were granted.]
[struck: issues a license under section 262 of title 42]
[struck: for a drug designated under section 360bb of this title for a rare disease or condition, the Secretary may not approve another application under section 355 of this title or issue another license under section 262 of title 42 for the same drug for the same approved use or indication within such rare disease or condition for a person who is not the holder of such approved application or of such license until the expiration of seven years from the date of the approval of the approved application or the issuance of the license. Section 355(c)(2)1 of this title does not apply to the refusal to approve an application under the preceding sentence.]
(b) Exceptions During [struck: the][inserted: any] [struck: 7-year][inserted: exclusivity] period described in subsection (a) for an approved application under section 355 of this title or license under section 262 of title 42, the Secretary may approve an application or issue a license for a drug that is otherwise the same, as determined by the Secretary, as the already approved drug for the same approved use or indication for which such 7-year period applies to such already approved or licensed drug if—
(1) the Secretary finds, after providing the holder of exclusive approval or licensure notice and opportunity for the submission of views, that during such period the holder of the exclusive approval or licensure cannot ensure the availability of sufficient quantities of the drug to meet the needs, relating to the approved use or indication, of persons with the disease or condition for which the drug was designated; or
(2) the holder provides the Secretary in writing the consent of such holder for the approval of other applications or the issuance of other licenses before the expiration of such seven-year period.
Rest of § 360cc unchanged ·